Accordingly, understanding the molecular mechanisms involved in TRAIL resistance in cancer cells and developing novel anti-cancer drugs that synergize with the various cancer cell responses to TRAIL are prerequisites for a more extensive and successful application of TRAIL-based therapies in the future [10–13]. The gene discussed is TNFSF10; the disease is cancer.